KRTL Biotech Highlights Pediatric Product Line to Support Childhood Wellness and Global Public Health
- KRTL Biotech
- Oct 7
- 3 min read
The pediatric catalog—developed and manufactured under GMP-certified protocols in Bolivia—includes antipyretics, analgesics, antitussives, antihistamines, multivitamins, and iron supplements, offered in syrups, drops, chewables, and powder sachets. Designed with age-appropriate dosing, flavoring, and formats, these products meet the therapeutic and practical requirements of pediatric patients, caregivers, and physicians alike.
"Children have specific healthcare needs, and our pediatric line is built with that sensitivity in mind," said Daniel Bishop, CEO of KRTL Biotech. "From formulation to packaging, every product is created to support early intervention, better adherence, and trusted outcomes."
These formulations are already used in Bolivian pharmacies and clinics, and many are supported by national procurement programs, reinforcing their safety, accessibility, and therapeutic value.
KRTL Biotech is currently preparing regulatory evaluation of select pediatric products for U.S. market entry, including possible alignment with OTC monograph pathways, where appropriate. The Company also sees strategic opportunity to supply these pediatric medicines to health ministries and NGOs throughout the Americas, particularly in support of public health campaigns targeting childhood nutrition and infection management.
"Pediatric care has always been central to our mission at SIGMA," said Patricia Wilstermann, CEO of SIGMA. "By delivering formulations designed specifically for children’s needs, we aim to support families, strengthen public health, and contribute to healthier futures for the next generation."
"Providing pediatric care options that are both high quality and affordable is central to our mission," said Cesar Herrera, CEO of KRTL Holding Group Inc. "This product line directly supports one of the most underserved and impactful areas of healthcare."
The pediatric portfolio includes:
Acetaminophen and ibuprofen syrups (fever and pain management)
Iron and multivitamin supplements (childhood development)
Antiallergics and cough syrups (respiratory support)
Digestive aids and electrolyte solutions (rehydration and GI care)
KRTL Biotech’s pediatric medicines exemplify the Company’s core values: scientific integrity, operational compliance, and cross-border scalability.
About KRTL Holding Group, Inc.
KRTL Holding Group, Inc. (OTC: KRTL) operates through its subsidiaries KRTL Biotech, Inc. and KRTL International Corp. The Company leverages strategic synergies across biotech, technology, and emerging markets to drive growth and deliver shareholder value.
About KRTL Biotech, Inc.
KRTL Biotech, Inc. focuses on building scalable life-science operations that prioritize quality, compliance, and innovation. The company aims to expand its international footprint while maintaining rigorous U.S. reporting and regulatory standards.
About Industria Químico Farmacéutica SIGMA Corp SRL
SIGMA is a Bolivian pharmaceutical manufacturer with more than five decades of experience in formulation, quality manufacturing, and commercialization of essential and complementary health products, including pharmaceuticals and nutraceuticals.
For more information:
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. Words such as “anticipates,” “will,” “believes,” “plans,” “expects,” “intends,” “projects,” “estimates,” “future,” and “opportunity” and similar expressions are used to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance. These risks and uncertainties include, but are not limited to, changes in regulatory requirements, market conditions, and other factors described in the Company’s filings. Additional information concerning risks and uncertainties that could materially affect KRTL’s business and financial results is included in the Company’s filings with the OTC Markets and, where applicable, the SEC. You should not place undue reliance on forward-looking statements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Comments